
Commentary|Articles|June 24, 2026
ADA 2026: Diabetes Technology Innovations Expand Beyond Traditional CGM Use
Fact checked by: Gillian McGovern, Editor, Ron Panarotti
As these tools continue to move into mainstream diabetes management, it is increasingly important that pharmacists have proficiency.
Advertisement
Advertisement
The technology presentations at the 86th American Diabetes Association (ADA) Scientific Sessions highlighted a major shift in diabetes care. Continuous glucose monitoring (CGM) is moving beyond intensive insulin management and becoming a broader therapeutic tool for people with type 2 diabetes (T2D), while automated insulin delivery systems continue to expand and emerging ketone monitoring technologies promise to improve safety and reduce the risk of diabetic ketoacidosis (DKA).
Related to this article

From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.

Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.

A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.

Nicole Albanese, PharmD, explains how a structured testing schedule and simple notes help patients bring useful glucose data to their care team.

Safe storage and responsible disposal help protect patients from accidental poisoning and drug misuse while keeping medications stable and effective.
Advertisement
Advertisement



